Thumbnail Image
Publication

Comment on PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia

Perrotti, Danilo
; 
Agarwal, Anupriya
; 
Lucas, Claire
; 
Narla, Goutham
; 
Nevanini, Paolo
; 
Odero, Maria D.
; 
Ruvolo, Peter P.
; 
Verrills, Nicole M.
Advisors
Editors
Other Contributors
Affiliation
University of Maryland; Imperial College London; Oregon Health and Science University; University of Chester; University of Michigan; University of Southern California; University of Navarra; MD Anderson Cancer Center; University of Newcastle
EPub Date
Publication Date
2019-07-17
Submitted Date
Collections
Chester Medical School
Show all metadata
Other Titles
Abstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.
Citation
Perrotti, D., Agarwal, A., Lucas, C. M., Narla, G., Neviani, P., Odero, M. D., ... & Verrills, N. M. (2019). Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”. Science translational medicine, 11(501), eaau0416. https://doi.org/10.1126/scitranslmed.aau0416
Publisher
American Association for the Advancement of Science
Journal
Science Translational Medicine
Research Unit
URI
http://hdl.handle.net/10034/624385
DOI
10.1126/scitranslmed.aau0416
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
This article is not available on ChesterRep.
Series/Report no.
ISSN
1946-6234
EISSN
1946-6242
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
Additional Links
https://www.science.org/doi/10.1126/scitranslmed.aau0416